HED-Start: Evaluating a Positive Skills Intervention for Patients New on Haemodialysis

Sponsor
Nanyang Technological University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04774770
Collaborator
National Kidney Foundation, Singapore (Other)
148
1
2
16.7
8.9

Study Details

Study Description

Brief Summary

Hemodialysis patients often experience barriers and misperceptions that hinder adjustment to life on dialysis. This study seeks to explore a group-based intervention (titled HED-Start) developed to improve self-care and emotional wellbeing among incident hemodialysis patients.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: HED-Start
N/A

Detailed Description

There are potentially modifiable psychosocial barriers and misperceptions about life on dialysis that hinder adjustment outcomes. It is hypothesized that these may include: poor understanding on what is needed or 'how to implement treatment principles', misperceptions related to disease and treatment, catastrophizing beliefs about impact of dialysis and low level of confidence on ability to manage treatment regime and renegotiate life roles as a "dialysis patient".

This study seeks to explore the feasibility and acceptability of implementing a two-arm parallel randomized controlled trial of a group-based intervention (titled HED-Start). HED-Start is specifically developed to reduce psychological distress and support self-care and self-management outcomes in incident hemodialysis patients.

Drawing on self-management and motivational interviewing principles paradigm, the HED-Start program aims to facilitate acquisition of skills and knowledge to support and improve self-care and emotional adjustment outcomes.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
148 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Care Provider, Outcomes Assessor)
Masking Description:
Care providers (dialysis nurses) and outcomes assessors (research staff conducting the baseline and follow-up questionnaires) will be blinded to participant allocation.
Primary Purpose:
Supportive Care
Official Title:
HED-Start: A Randomised Controlled Trial to Evaluate a Positive Skills Intervention for Patients New on Haemodialysis
Anticipated Study Start Date :
May 1, 2021
Anticipated Primary Completion Date :
Sep 22, 2022
Anticipated Study Completion Date :
Sep 22, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: HED-Start Intervention arm

Participants assigned to the intervention arm will undergo 4 sessions of the HED-Start program. Each session is 2 hours long and will be conducted fortnightly.

Behavioral: HED-Start
The HED-Start Program is a cognitive-behavioral intervention based on self-management and motivational interviewing principles.

No Intervention: Standard care arm

Participants assigned to the standard care arm will proceed with routine standard care.

Outcome Measures

Primary Outcome Measures

  1. Change in Anxiety and Depression (HADS) scores from baseline [Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization]

    Hospital Anxiety and Depression Scale (HADS). The HADS comprises two subscales (anxiety; depression) and can be totaled to produce an overall scale score. Scores range from 0 to 21 for each subscale, and from 0 to 42 for the overall score. Higher scores are indicative of worse anxiety and depression symptoms.

Secondary Outcome Measures

  1. Change in Quality of life (WHOQOL-BREF) scores from baseline [Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization]

    World Health Organization Quality of Life instrument (WHOQOL-BREF). Two global items (overall quality of life; general health) and two subscales (psychological health; social relationships) from the WHOQOL-BREF are used. Global scores range from 1 to 5, while subscale scores range from 4 to 20. Higher scores indicate better quality of life.

  2. Change in kidney disease-related quality of life (KDQOL-SF) scores from baseline [Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization]

    Kidney Disease Quality of Life instrument (KDQOL-SF). The Burden of Kidney Disease subscale from the KDQOL-SF will be administered. Scores range from 0 to 100, with a higher score reflecting better quality of life.

  3. Change in Illness Perception scores from baseline [Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization]

    Brief Illness Perception Questionnaire (BIPQ). The BIPQ consists of 8 subscales (i.e., Consequence, Timeline, Identity, Personal Control, Treatment Control, Concern, Coherence, and Emotional Representation). Subscale scores range from 0 to 10, with higher scores reflective of more negative illness perceptions.

  4. Change in Positive and Negative Affect scores from baseline [Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization]

    Scale of Positive and Negative Experience (SPANE). The SPANE comprises 6 items assessing positive affect and 6 items assessing negative affect. Subscale scores range from 6 to 30. Higher scores in the Positive and Negative affect subscale indicate greater positive and negative affect respectively.

  5. Change in Self-Efficacy for Managing Chronic Disease 6-item Scale scores from baseline [Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization]

    Self-Efficacy for Managing Chronic Disease 6-item Scale. The overall scale score ranges from 1 to 10. Higher scores reflect greater self-efficacy.

  6. Change in Benefit finding in hemodialysis (BFS) scores from baseline [Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization]

    Benefit Finding Scale (BFS). Two subscales (personal growth; acceptance) and an overall score can be computed. All scores range from 1 to 4, with a higher score reflecting a greater extent of benefit finding.

  7. Change in Resilience scores from baseline [Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization]

    2-item Connor-Davidson Resilience Scale (CD-RISC-2). The CD-RISC-2 score ranges from 0 to 8. Higher scores indicate greater resilience.

  8. Change in Health Education Impact Questionnaire scores from baseline [Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization]

    Health Education Impact Questionnaire (heiQ). Six subscales from the heiQ (Positive and Active Engagement in Life, Skill and Technique Acquisition, Constructive Attitudes and Approaches, Self-Monitoring and Insight, Health Services Navigation, and Social Integration and Support) will be used to assess other self-management skills. Scores range from 1 to 4. Higher scores indicate greater proficiency with the relevant skill domain.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients diagnosed with end-stage kidney disease (ESKD) and established on hemodialysis with the National Kidney Foundation Singapore (NKF) for fewer than 90 days

  • At least 21 years old

  • Proficient in spoken and written English or Mandarin

Exclusion Criteria:
  • Unwilling or unable to give informed consent or refuse to be randomized

  • Have cognitive impairments or psychiatric conditions that preclude consent

  • Are currently involved in other intervention trials

  • Are failing on dialysis and approaching end of life (supportive/palliative care pathway)

Contacts and Locations

Locations

Site City State Country Postal Code
1 National Kidney Foundation Singapore Singapore Singapore

Sponsors and Collaborators

  • Nanyang Technological University
  • National Kidney Foundation, Singapore

Investigators

  • Principal Investigator: Konstadina Griva, PhD, Nanyang Technological University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Konstadina Griva, Associate Professor of Health Psychology and Behavioural Medicine, Nanyang Technological University
ClinicalTrials.gov Identifier:
NCT04774770
Other Study ID Numbers:
  • NKFRC/2018/01/02
First Posted:
Mar 1, 2021
Last Update Posted:
May 10, 2021
Last Verified:
May 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 10, 2021